2023-01-31 18:46:00

EnGeneIC publishes the COVID-EDV vaccines novel mechanism of action in a leading Immunology journal

Logo GlobeNewswire
  • Protects against mutant strains
  • Promotes a long term memory response
  • No side effects in healthy volunteers
  • Vaccine stored and transported at room temperature with long shelf life
  • Seeking immune-compromised patients for next human trial

SYDNEY, Australia and NEW YORK, Jan. 31, 2023 (GLOBE NEWSWIRE) -- The completely unique mechanism of action of the worlds first COVID-19 vaccine to stimulate high affinity antibodies which neutralise most COVID variants has been published by EnGeneIC in the prestigious journal, Frontiers in Immunology (27th January, 2023). This paper illustrates that the COVID-EDV vaccine is a fundamental change in thinking on how to produce an effective and inexpensive vaccine and has broad-reaching ramifications for vaccinology.

EnGeneIC, an Australian clinical stage biotechnology company, has developed therapeutics for end stage patients with low survival cancers based on its revolutionary and world first EDVnanocell cyto-immunotherapy platform (EDV; EnGeneIC Dream Vector).More recently, the company discovered that the same EDV nanocell can deliver viral antigens, resulting in its novel COVID-EDV vaccine.

The paper describes for the first time in mice and humans, that EDVs packaged with Spike-protein and a glycolipid, stimulate an alternate anti-viral immune pathway, differing from all existing vaccines and involving an orchestra of immune cells. COVID-EDV produces high affinity antibodies which strongly latch on to the virus, even when it mutates, whereas other vaccines make low affinity antibodies that only bind to the COVID strain which they are directed against and fall off if the virus has a mutant Spike protein. EnGeneICs results indicate that COVID-EDV neutralizes 90-100% of ancestral and variants of concern (VOCs) in mice and in human trial volunteers, including neutralization of Omicron BA 4/5. Blood analysis also revealed long lasting Spike-specific memory B and T cells.

EnGeneIC is currently conducting trials of its groundbreaking vaccine in Sydney and Melbourne and has vaccinated 80 volunteers. After two doses, 3 weeks apart, the majority of participants have passed the 3- month post vaccination safety assessment and importantly, they have high affinity antibodies capable of neutralising all COVID mutants, including Omicron.

Principal Clinical investigator Professor Kumar Visvanathan from St Vincents Hospital, Melbourne, who is a co-author on the paper, noted, We are very pleased to be part of this study, where healthy volunteers have not been experiencing any side effects and are broadly protected against all the COVID mutant strains. This is an Australian innovation and the Joint CEOs and founders of EnGeneIC, Drs Jennifer MacDiarmid and Himanshu Brahmbhatt have been very persistent in translating this exciting vaccine approach into clinical trials.

In October, 2022, EnGeneIC was announced as the winner of the Australian Financial Review Most Innovative company in Healthcare in Australia and New Zealand, based on the COVID-EDV vaccines novel mechanism of action, clinical results and the companys trials treating late-stage cancer patients who are immune-compromised and where EDVs stimulate a strong immune response.

Dr. Brahmbhatt said, So, rather than compete with Big Pharma, EnGeneIC is targeting the immune-compromised population who dont respond well to current vaccines and are vulnerable to severe disease and morbidity. Many of these people are too stressed and concerned about the consequences of getting COVID we strongly believe that we can help. Globally, over 4% of the population including those with cancer, organ transplant, rheumatoid arthritis, those taking steroids and other immune-depressing drugs are immune-compromised and a staggering 20% of those over 70 falls into this category.

Ethics approval has been granted for a COVID-EDV trial in immune-compromised people in Sydney, Melbourne and Perth and volunteers are now being sought for this important trial. Additionally, the vaccine can be stored and transported at room temperature and has more than 18 months shelf-life, making it particularly attractive for remote areas and developing nations where transport and storage is difficult.

For more information, images, animations, high-res footage and interviews, please contact ernestine@gemaker.com.au (0411) 691 241

For trial information, please contact COVID-EDV.Trial.Enquiries@engeneic.com

About EnGeneIC and the EDV Nanocell Technology
EnGeneIC is a clinical stage biopharmaceutical company advancing its proprietary EDV (EnGeneIC Dream Vector) nanocells for oncology and infectious disease applications. The EDV is a powerful nanoparticle drug, siRNA, or miRNA delivery platform designed to directly target and effectively kill tumour cells with minimal toxicity, while simultaneously stimulating the immune system's innate and adaptive anti-tumour response. EnGeneIC is now in Phase IIa clinical trials in patients with intractable low survival cancers, including patients with metastatic pancreatic cancer. www.engeneic.com

Continue read on globenewswire.com

Logo BBC
HealthBy Https://Www Facebook Com/Bbcnews2023-01-31 06:13:03
Richard Westcott Science correspondent, BBC News, East Published 2 minutes ago Cambridge researchers are continuing to regularly take blood from more than...

Logo PR Newswire
HealthPress Release2023-01-30 21:03:00
Promising results of preclinical research on a fully synthetic vaccine designed by Artificial Cell Technologies are published in the journal Vaccines NEW...

Logo EIN Presswire
HealthPress Release2023-01-31 11:18:30
The report provides a comprehensive analysis of the impact of the pandemic across the industry and an overview of the market scenario after COVID-19. NEW...

Logo The Conversation US
HealthBy Matthew Woodruff2023-01-25 13:25:09
By almost any measure, the vaccination campaign against SARS-CoV-2, the virus that causes COVID-19, has been a global success. As of January 2023, more than...

Logo Fortune
Business / FinanceBy Zeke Miller2023-01-30 23:31:01
Once the emergency expires, people with private insurance, along with the uninsured, will have to pay more for vaccines and tests.

Logo EIN Presswire
HealthPress Release2023-01-31 08:59:35
Encephalitis Vaccine Market Global Encephalitis Vaccine Market Opportunity on Top Manufacturing Industries in 2023-2030: Market.Biz NEW YORK, NY, UNITED...

Logo PR Newswire
HealthPress Release2023-01-31 15:16:00
BALTIMORE, Jan. 31, 2023 /PRNewswire/ -- STAT today published " How the Biden Administration's COVID preparedness policies could narrow America's political...

Logo The Guardian
HealthBy Guardian Staff Reporter2023-01-27 01:42:36
The US is poised to make Covid-19 vaccinations more like a yearly flu shot, a major shift in strategy despite a long list of questions about how to best...

Logo PR Newswire
HealthPress Release2023-01-30 19:35:00
OTTAWA, ON, Jan. 30, 2023 /CNW/ - The Public Health Agency of Canada (PHAC) is issuing this statement to provide an update on the ongoing response to...

Logo EIN Presswire
HealthPress Release2023-01-26 11:00:00
QYNDR Vaccine Can Survive the Acidity of the Stomach and Reduces Viral Shedding

Logo Benzinga
PoliticsBy Vandana Singh2023-01-31 13:26:37
The Biden administration will allow the ongoing Covid-19 emergency declarations to end on May 11, the White House announced on Monday, as the U.S. shifts...

Logo Benzinga
Business / FinanceBy Business Wire2023-01-30 19:00:00
Industry veteran, Tyler Martin, M.D., appointed as chief executive officer Management includes key members of the team that developed Prevnar vaccines...

PoliticsBy Lauran Neergaard2023-01-26 23:08:26
The U.S. is poised to make COVID-19 vaccinations more like a yearly flu shot, a major shift in strategy despite a long list of questions about how to best...

Logo Daily Mail
HealthBy Emily Stearn2023-01-25 14:00:45
Another round of Covid booster jabs should be dished out this autumn, the Government's scientific advisers said today. Health chiefs also called for those...

HealthBy Katherine Ellen Foley2023-01-31 18:30:20
Pharmaceutical giant Pfizer expects billions less in revenue this year as the U.S. government stops buying its Covid-19 vaccine and treatments and fewer...

Business / FinanceBy Spencer Kimball2023-01-30 23:38:24
U.S. President Joe Biden delivers remarks on the coronavirus disease (COVID-19) before receiving a second COVID-19 booster vaccination in the Eisenhower...

Logo BBC
HealthBy Https://Www Facebook Com/Bbcnews2023-01-31 06:20:38
By Ollie Pritchard-Jones BBC News A long Covid sufferer is using photography to help her live with the condition. Tania McCrea-Steele says she has had three...

Logo U.S. News & World Report
PoliticsBy Cecelia Smith Schoenwalder2023-01-25 21:30:34
The updated COVID-19 booster shots are at least 40% effective against symptomatic infection from omicron subvariants XBB.1.5 and XBB among fully vaccinated...

Logo CBS News
HealthBy Alexander Tin2023-01-26 21:44:40
A panel of the Food and Drug Administration's outside vaccine advisers voted unanimously Thursday in favor of "harmonizing" the initial shots given to...

Logo BBC
HealthBy Https://Www Facebook Com/Bbcnews2023-01-24 21:29:45
By Fiona Lamdin & Lee Madan BBC News Vulnerable people who have had a third Coronavirus vaccine, or booster, have a significant increase in antibodies...